Regenn® Therapy System Safety Study

Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-80
SponsorProgenerative Medical, Inc

About this trial

The goal of this clinical trial is to evaluate the safety of the investigational device, Regenn® Negative Pressure Therapy System (Regenn® Therapy), a form of Negative Pressure Wound Therapy (NPWT), in the post-operative surgical wounds of patients undergoing lumbar spinal fusion surgeries. The main questions the study aims to answer are:

* The device-related serious adverse event rate. * Patient post-operative pain as assessed using a validated pain measurement scoring system. * The number and type of adverse events. * The rate of delayed seroma formation.

Participants will

* Be screened for their suitability to participate in the investigational study using questions about their health, medical history, and current medications. * Undergo a physical exam, an assessment of patient vital signs and routine blood analyses. * Complete an Informed Consent Form if selected to participate in the investigational study. * Be randomly assigned to the different study arms. * Not change the operation of their respective device or to disturb components of their device. * Notify their surgeon or designated healthcare provider should they have any questions or encounter any issues with their device. * Attend two post-operative visits at approximately one month and three months.

Eligibility criteria

Qualifiers

Subject has provided written informed consent on a form reviewed and approved by the Institutional Review Board for the clinical site.

The subject is 18 - 80 years old.

Instability (defined as angulation ≥ 5 degrees and/or translation ≥ 3mm on flexion/extension radiographs;

Osteophyte formation of facet joints or vertebral endplates;

Disqualifiers

Subject is unable or unwilling to provide informed consent or is unable to conform to the study protocol follow-up procedures and visits.

Subject has a contraindication (including allergic reaction) to antiplatelet/anticoagulant medications, nickel, titanium, bone allograft, or blood transfusion that is not amenable to pretreatment with steroids or/and antihistamines.

Subject has a history of bleeding diatheses or coagulopathy.

Subject has concomitant hepatic insufficiency, thrombophlebitis, uremia, systemic lupus erythematosus (SLE), or any autoimmune diseases.

Trial design

Treatments tested in this trial

  • Regenn® Negative Pressure Therapy System
  • Prevena™ Incision Management System

Treatment groups

30 Participants
are divided into 2 treatment groups

Sponsors and collaborators